Treeline Biosciences is a privately held, clinical-stage biopharmaceutical company dedicated to developing innovative treatments for cancer and other serious diseases. Utilizing advanced computational tools and proven drug approaches, Treeline focuses on creating therapies that target compelling disease mechanisms. The company's pipeline includes small molecules, protein degraders, and targeted therapy antibody-drug conjugates (ADCs), with current programs addressing conditions such as lymphoma and KRAS-mutated cancers. Led by experienced oncologists and R&D leaders, Treeline operates across the U.S. and Europe, aiming to redefine treatment paradigms in oncology and beyond.
Leadership & Board
Key Executives
SVP Corporate DevelopmentSpencer Smith
Co-Founder & CSOJeffrey Engelman
CEO & Co-FounderJosh Bilenker
Current Number of Employees164
Current LinkedIn Followers10,541
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$200M
Total Amount Raised$200M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$200M
Latest Funding Amount$200M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Treeline Biosciences had 164 employees as of April 6, 2026. The number of employees increased by 0 (0.00%) week-over-week.
164Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Treeline Biosciences had 10,541 followers as of April 6, 2026. The number of followers increased by 16 (0.15%) week-over-week.
10,541Latest Followers Count
16(0.15%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.